| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PIK3R2 |
| Uniprot No | O00459 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 75-125aa |
| 氨基酸序列 | VEFLGPVALARPGPRPRGPRPLPARPRDGAPEPGLTLPDLPEQFSPPDVAP |
| 预测分子量 | 36.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PIK3R2重组蛋白的3篇参考文献示例(注：文献为示例性概括，实际引用需核实原文)：
---
1. **文献名称**：*Structural insights into the regulation of PI3Kα by p85β*
**作者**：Zhang X, et al.
**摘要**：通过重组表达人源PIK3R2(p85β)蛋白，结合冷冻电镜技术解析其与PI3Kα催化亚基的复合物结构，揭示了p85β通过SH2结构域调控PI3K活性的分子机制，为靶向PI3K信号通路的药物设计提供依据。
---
2. **文献名称**：*Functional characterization of PIK3R2 mutations in neurodevelopmental disorders*
**作者**：Chen L, et al.
**摘要**：研究利用重组PIK3R2蛋白进行体外激酶实验，发现多种与巨脑畸形相关的PIK3R2突变体导致PI3K-AKT通路异常激活，揭示了其通过增强p85β与p110亚基结合促进下游信号传导的病理机制。
---
3. **文献名称**：*Recombinant expression and purification of human PIK3R2 for biochemical assays*
**作者**：Wang Y, et al.
**摘要**：优化了PIK3R2重组蛋白在昆虫细胞中的表达与纯化流程，验证其与PI3K催化亚基的结合活性，为高通量筛选PI3K抑制剂提供了高纯度蛋白工具。
---
4. **文献名称**：*p85β regulates autophagy via mTORC1 signaling in cancer cells*
**作者**：Kim S, et al.
**摘要**：通过重组PIK3R2蛋白及敲除模型，证明p85β通过mTORC1通路调控肿瘤细胞自噬，其缺失导致AKT依赖性自噬抑制，影响癌细胞存活。
---
**注意**：上述内容为基于领域研究的示例性概括，实际文献需通过学术数据库(如PubMed、Web of Science)检索确认。
**Background of PIK3R2 Recombinant Protein**
PIK3R2 (phosphoinositide-3-kinase regulatory subunit 2) is a regulatory subunit of class IA phosphatidylinositol 3-kinases (PI3Ks), which play critical roles in intracellular signal transduction pathways. The PI3K complex, composed of a catalytic (p110) and regulatory subunit (e.g., PIK3R2), regulates cellular processes such as growth, survival, metabolism, and apoptosis by generating phosphatidylinositol (3.4.5)-trisphosphate (PIP3) as a secondary messenger. PIK3R2. also known as p85β, stabilizes the p110 catalytic subunit and modulates PI3K activity in response to receptor tyrosine kinase activation.
Recombinant PIK3R2 protein is engineered *in vitro* using expression systems (e.g., *E. coli* or mammalian cells*) to produce purified, functional protein for research applications. Its production often involves cloning the human *PIK3R2* gene into expression vectors, followed by affinity chromatography purification. This recombinant tool enables the study of PI3K-AKT-mTOR signaling dysregulation, a hallmark of cancers, metabolic disorders, and neurological conditions.
Mutations in *PIK3R2* are linked to developmental syndromes (e.g., megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome) and cancer. Recombinant PIK3R2 proteins, including wild-type or mutant variants, help dissect molecular mechanisms of disease, screen therapeutic inhibitors, or validate diagnostic biomarkers. Additionally, they aid in structural studies to map protein-protein interaction domains (e.g., SH2. inter-SH2 regions) critical for PI3K assembly and membrane localization.
As a key reagent in signal transduction research, PIK3R2 recombinant protein supports drug discovery targeting PI3K-driven pathologies while offering insights into cellular homeostasis and disease pathogenesis.
×
